Inari Medical plans to pay up to $415m for Paris-based LimFlow SA to add the LimFlow transcatheter deep-vein arterialization system to its portfolio of peripheral vascular interventional devices, the companies announced on 1 November.
“Our ethos and mission are focused on addressing significant unmet needs and thinking big,” Inari CEO Andrew Hykes said during Inari’s third-quarter 2023 earnings calls on 1 November. “LimFlow is...
LimFlow CEO Dan Rose said, “By joining with Inari and benefitting from their exceptional resources and capabilities, we expect to be well-positioned to increase access to our technology and advance...